Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changes To The NHS: How Can Pharma Best Position Itself?

Executive Summary

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
Advertisement

Related Content

New U.K. NHS Bodies Authorize Avastin Use In AMD As Lucentis Pricing Pressures Continue
Spanish Pharma Industry Appeals Local Drug Funding Decisions
NICE Likely To Lose Cost-Watchdog Status By 2013
Pay-For-Performance Hits France As Part Of Cost-Cutting Measures
Pay-For-Performance Hits France As Part Of Cost-Cutting Measures

Topics

Advertisement
UsernamePublicRestriction

Register

PS053072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel